Table 3.

Change in kidney function and biomarkers among participants in the follow-up study (n=198)

VariablesPatients before Follow-UpPatients after Follow-UpP Value
CRP, mg/L56.2 (26.9–105.5)3.9 (1.3–17.8)<0.001a
Serum albumin, g/L34.4±5.033.4±5.30.10b
BUN, mmol/L4.7 (3.5–5.9)4.6 (3.8–6.6)0.07a
SCR, μmol/L74.0 (61.0–89.0)72.5 (60.0–85.0)0.29a
Lymphocytes, 109/L0.80 (0.59–1.12)1.36 (0.87–1.82)<0.001a
Eosinophils, 109/L0.00 (0.00–0.06)0.00 (0.07–0.29)<0.001a
Serum IL-10, pg/ml6.7 (5.0–13.1)5.0 (5.0–5.2)0.01a
Serum IL-6, pg/ml24.3 (12.6–57.6)4.8 (2.0–22.4)0.008a
Serum IL-2R, U/ml794 (552–1065)505 (277–720)<0.001a
Proteinuria<0.001a
 None21/198 (10.6%)132/198 (66.7%)
 ±/+146/198 (73.8%)40/198(20.2%)
 ++/+++31/198 (15.6%)4/198 (2.0%)
Hematuria<0.001a
 None89/198 (44.9%)133/198 (67.2%)
 ±/+84/198 (42.4%)33/198 (16.7%)
 ++/+++25/198 (12.6%)10/198 (5.1%)
AKI<0.001a
 No163/198 (82.3%)179/198 (90.4%)
 AKI stage 116/198 (8.1%)6/198 (3.0%)
 AKI stage 28/198 (4.0%)4/198 (2.0%)
 AKI stage 311/198 (5.6%)9/198 (4.5%)
Resolution on lung involvement118/198 (59.6%)
Death29/198 (14.6%)
Death in critically ill group29/56 (51.8%)
  • Data are presented as mean±SD or median (25th–75th percentiles) or as number and percentage. SCR, serum creatinine; ±/+, ± approximately 1+; ++/+++, 2+ approximately 3+.

  • a Wilcoxon signed-rank test.

  • b Paired t test.